Search Results
Myeloid Growth Factor Guidelines: Moving Toward a Societal Perspective
Rodger J. Winn
Erratum
In the September 2023 issue of JNCCN , in the article “Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy” by Blayney et al ( J Natl Compr Canc Netw 2023;21[9]: 945
Moving Forward With Myeloid Growth Factors
Jeffrey Crawford
, the NCCN Guidelines Panel initially established the febrile neutropenia threshold for use of myeloid growth factors at 20%; this standard has now been adopted by virtually all other guidelines committees. Moreover, it was the NCCN Panel who stressed
CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, and Pankit Vachhani
in those who developed TLS. No significant association was found between Ven ramp up and TLS incidence. 42(37.8%) had known infections prior to starting HMA+Ven. 41 patients (36.9%) were diagnosed with febrile neutropenia; 36 (32.4%) had confirmed
CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan
Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung, and Taewoong Choi
-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia
Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, but Must Be Used Wisely
Eric J. Bow
consequences for patients . Cancer 2004 ; 100 ( Suppl ): 1995 – 2025 . 13 Bodey GP . The treatment of febrile neutropenia: from the Dark Ages to the present . Support Care Cancer 1997 ; 5 : 351 – 357 . 14 Schimpff SC Satterlee W
Myeloid Growth Factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland
Overview Neutropenia (< 500 neutrophils/mcL or < 1000 neutrophils/mcL and a predicted decline to < 500/mcL over the next 48 hours) and resulting febrile neutropenia (≥ 38.3°C orally or ≥ 38.0°C over 1 hour) can be induced by myelosuppressive
Antibacterial Prophylaxis in Patients with Neutropenia
Brahm H. Segal and Alison G. Freifeld
-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP
Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer
Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Annissa DeSilva, Aatur D. Singhi, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, and Amer H. Zureikat
nonmyeloid cancer receiving chemotherapy who are at risk for or displaying signs of febrile neutropenia. 3 – 5 G-CSF prophylaxis and treatment varies in clinical practice and is highly dependent on patient performance status and comorbidities, chemotherapy
Identification of Risk Factors for Chemotherapy-Related 30-Day Readmissions
Jeremy Lund, Angela Pearson, and Georgia Keriazes
readmitting diagnosis or ICD-9 code. Criteria for CRR included diagnosis of febrile neutropenia, other known toxicity of administered chemotherapy agent, and documented diagnosis of CRR by the oncologist. A multidisciplinary panel (medical oncologist, oncology
